Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
Melinda A PruisM S PaatsW R R GeurtsHendrikus Jan DubbinkAnne-Marie C DingemansPublished in: JCO precision oncology (2022)